In-vitro drug release study: preparation and evaluation of chitosan anchored nanoparticles
Cancer has become a solemn threat to the life of human beings universally. Various strategies are available to steadfastness cancer; however they are not so effective owed to their serious side effects, noxious effect to healthy cells and non- specificity to cancer cells targeting. To tenacity above facts we try to deed inherent characters of cancer cells. HA was used as a targeting agent for drug delivery to breast cancer cells. In this work nanoparticles were equipped using chitosan and sodium tripolyphosphate encapsulating methotrexate. Methotrexate (Mtx) a folic acid antagonist that inhibits dihydrofolatereductase (DHFR) and blocks conversion of dihydrofolic acid (DHFA) to tetrahydrofolic acid (THFA) of the cell cycle. Chitosan anchored nanoparticles were prepared by ionotropic gelation method by means of sodium tripolyphosphate and evalauted for in-vitro drug release study with dialysis membrane. Result depicts that drug releases from chitosan nanoparticles in sustained manner over a prolonged episode of time from the NPs as the medium acidity enhanced at the target site, not in plasma. In conclusion, chitosan anchored nanoparticles of MTX could be well thought-out as probable candidate for drug delivery in the treatment of breast cancer.
Keywords: Breast cancer, Methotrexate, Chitosan, TPP and Nanoparticles.
3. Thakur CK, Thotakuraa N, Kumar R, Kumar P, Singh B, Chitkara D and Razaa. K: Chitosan-modified PLGA polymeric nanocarriers with better delivery potential for tamoxifen. International Journal of Biological Macromolecules 2016; 93:81–389.
4. Kaur I and Agrawal R: Nanotechnology: a new paradigm in cosmeceuticals. Recent Pat. Drug Deliv. Formul 2007; 171–182.
5. Baptista PV: Cancer nanotechnology − prospects for cancer diagnostics and therapy. Curr. Cancer Ther. Rev.2016; 5:80–88.
6. Faraji AH and Wipf P: Nanoparticles in cellular drug delivery, Bioorg. Med. Chem. 2009; 17:2950–2962.
7. Raza K, Kumar D, Kiran C, Kumar M, Guru SK, Kumar P, Arora S, Sharma G, Bhushan S and Katare OP:Conjugation of docetaxel with multiwalled carbon nanotubes and co-delivery with piperine: implications on pharmacokinetic profile and anti-cancer activity. Mol. Pharm. 2016; 13:2423–2432.
8. Krishnaveni B. Chitosan: A review on its varied novel therapeutic and industrial applications. Journal of Drug Delivery and Therapeutics, 2016; 6(6):70-79.
9. Kumar P, Raza K, Kaushik L, Malik R, Arora S and Katare OP: Role of colloidal drug delivery carriers in taxane-mediated chemotherapy: a review. Curr. Pharm. Des. 2016. http://dx.doi.org/10.2174/
10. Singh S, Sharma A and Robertson GP, Realizing the Clinical Potential of Cancer Nanotechnology by Minimizing Toxicologic and Targeted Delivery Concerns. Cancer Res. 2012; 72:5663−5668.
11. Raza K, Kumar M, Kumar P, Malik R, Sharma G, Kaur M and Katare O P: Topical Delivery of Aceclofenac: Challenges and Promises of Novel Drug Delivery Systems. BioMed Res. Int.: 2014.
12. Madani F, Goodarzi A, Hashemi M, Hashemi BM, Khosravani M and Adabi M:Preparation of Methotrexate loaded PLGA nanoparticles coated with PVA and Poloxamer188. Nanomed Res J 2018; 3:19-24.
13. Danhier F, Ansorena E, Silva JM, Coco R, and Le BA: PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161:505-522.
14. Moffat AC, Osselton MD and Widdop B: Clarke’s analysis of drugs and poisons. Pharmaceutical Press, London 2011.
15. Zhang Y, Jin T and Zhuo RX: Methotrexate-loaded biodegradable polymeric micelles: Preparation, physicochemical properties and in-vitro drug release. Colloids Surf B Biointerfaces 2005; 44:104-109.
16. Goldman ID and Matherly LH: The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28:77-102.
17. Khan ZA, Tripathi R and Mishra B Methotrexate: A detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 2012; 9:151-169.
18. Needham D and Dewhirst MW: The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53:285-30
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).